Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923211 | 0.84 | GABRA1 (0.52) | GABRA1GABRB1LMNAGABRB2CA1 | |
| SCHEMBL22767491 | 0.77 | CYP1A2 (0.34) | GABRA1GABRB1LMNACYP1A2CYP3A4 | |
| SCHEMBL14803522 | 0.77 | GABRA1 (0.45) | GABRA1GABRB1LMNAGABRB2CA1 | |
| SCHEMBL23971152 | 0.76 | MAPT (0.33) | GABRA1GABRB1LMNAMAPT | |
| SCHEMBL20285922 | 0.76 | LMNA (0.36) | GABRA1GABRB1LMNASLC6A2HTR2B | |
| SCHEMBL26780057 | 0.76 | GABRA1 (0.39) | GABRA1GABRB1LMNAGABRB2CA1 | |
| SCHEMBL2681685 | 0.75 | — | — | |
| SCHEMBL19769016 | 0.74 | GAA (0.35) | GABRA1GABRB1LMNAMAPT | |
| SCHEMBL16248188 | 0.74 | GABRA1 (0.45) | GABRA1GABRB1LMNAGABRB2CA1 | |
| SCHEMBL13889413 | 0.74 | RPS6KA3 (0.34) | GABRA1GABRB1LMNARPS6KA3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | GABRA1 2729/4885GABRB1 3064/4885LMNA 691/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | GABRA1 2958/4885GABRB1 3211/4885LMNA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.